The North America AST market registered a revenue of 1,038 million USD in 2025, projected to climb steadily through 2035. Rising investments in healthcare infrastructure, emphasis on rapid diagnostics, and regulatory mandates for AST in infection control protocols are contributing to sustained market growth. Forecasts indicate continued double-digit CAGR, with market value expected to surpass 2,800 million USD by 2035 as modernization and adoption of automated and molecular testing platforms accelerate across healthcare and allied segments.
Read More - https://bussinessinsights.com/research-report/north-america-antimicrobial-susceptibility-testing-market
Clinical diagnostics accounts for the dominant share in AST applications in North America (2025), followed by drug discovery & development and epidemiology. The region’s high incidence of hospital-acquired infections and strong emphasis on infection control drive usage in clinical diagnostics. Drug discovery leverages AST for new compound screening, while epidemiological applications are growing due to heightened public health surveillance and tracking of resistance patterns. Additional expansion is seen in veterinary and environmental testing, reflecting the broader impact of antimicrobial resistance.
Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-antimicrobial-susceptibility-testing-market
Who are the key players in North America Antimicrobial Susceptibility Testing Market industry?
The top 5 key players in the North America Antimicrobial Susceptibility Testing Market are bioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation (Beckman Coulter), and Merck KGaA. These companies are leaders in diagnostics and laboratory solutions, delivering innovative testing platforms and expanding their regional presence.
What is the North America Antimicrobial Susceptibility Testing Market growth?
The North America Antimicrobial Susceptibility Testing Market has experienced steady growth in recent years, driven by rising antimicrobial resistance and increased adoption of automated testing systems. For instance, in 2023, BD (Becton Dickinson) introduced new solutions to streamline testing, spurring faster diagnostic turnaround and supporting market expansion.
Which segment accounted for the largest North America Antimicrobial Susceptibility Testing Market share?
The diagnostic laboratories segment accounted for the largest market share due to the increased demand for rapid and accurate antimicrobial susceptibility testing across hospitals and reference labs. Growing test volumes and centralized laboratory expansion have bolstered this segment's dominance in managing infectious diseases across North America.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com